Management characterizes the current period as a pivotal evolution with a significantly lowered risk profile following the ANNAFILM Complete Response Letter (CRL).

Performance attribution for the quarter was driven by a 10% revenue increase in manufacturing and supply, specifically from Suboxone and ONDEEF, despite a slight full-year decline due to prior-year one-time deferred revenue recognition.

The company has rapidly addressed CRL requirements within 31 days by contracting CROs, modifying packaging for easier opening, and finalizing protocols for human factors and PK studies.

Strategic positioning has shifted to prioritize ANNAFILM as the primary growth driver, leading to a decision to out-license Libervant in the U.S. to focus resources on the epinephrine launch.

The clinical team was significantly strengthened with the addition of world-renowned allergist Dr. Matt Greenhawk and seasoned development leader Dr. Matthew Davis to lead FDA interactions.

Management settled a nine-year defamation lawsuit, which they described as a strategic move to remove a long-standing distraction and simplify the company's legal workload.

The commercial strategy now includes a 50% increase in the planned sales force (from 50 to 75 reps) to deepen penetration into the allergist and high-decile pediatrician markets.

The company is committed to resubmitting the ANNAFILM NDA in the third quarter of 2026, assuming a successful Type A meeting with the FDA within the next 30 days.

Financial guidance for 2026 projects total revenue of $46,000,000 to $50,000,000 and an adjusted EBITDA loss of $30,000,000 to $35,000,000, excluding potential launch costs.

The RTW revenue-sharing agreement extension to June 2027 provides a capital safety net for the commercial launch, which management expects to be close to cash neutral by 2027.

International expansion remains a priority with planned regulatory filings for ANNAFILM in Europe and Canada before the end of 2026, following the U.S. resubmission.

The AQST-108 prodrug platform is expected to produce top-line clinical data in the near future, though its development timeline is secondary to the ANNAFILM launch.

RTW extended their $75,000,000 revenue-sharing agreement and made an additional $5,000,000 strategic equity investment, signaling institutional confidence.

The company ended 2025 with $121,200,000 in cash, which management believes provides sufficient runway for all 2026 development and regulatory objectives.

Aquestive successfully defended its data package as the FDA denied a competitor's citizen petition, which management views as a validating regulatory milestone.

The decision to increase the sales force to 75 reps is intended to eliminate 'white space' in geographic coverage and improve efficiency by reducing representative travel time.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expects the meeting by early April and seeks alignment on the two requested studies (human factors and PK).

They have already prepared protocols and are seeking only one minor clarification regarding the specific arms required for the PK study.

The expansion to 75 reps allows for deeper penetration into the pediatric market and higher frequency of visits to top-tier allergists.

Management noted this move reduces reliance on inside sales and increases territory efficiency, aiming for a cash-neutral commercial position by 2027.

New data presented at Quad AI suggests ANNAFILM does not cause the initial dip in diastolic blood pressure seen with injectable epinephrine, potentially improving mean arterial pressure during shock.

Management believes the competitor's heavy DTC spending is beneficial as it grows the overall non-needle market, which Aquestive intends to capture through direct physician engagement.

Management explicitly stated that ANNAFILM is the priority; they cannot humanly launch two products simultaneously, leading to the Libervant out-licensing strategy.

AQST-108 development will continue but will be paced to ensure it does not compete for resources required for the ANNAFILM resubmission.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.